Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Q3 FY2023 Earnings Presentation
28 slides from Piramal Pharma's earnings presentation, February 2023
Slide 1: Piramal Pharma Limited Q3 & 9M FY2023 Results
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Piramal Pharma Limited Q3 & 9M FY2023 Results February 2023
Slide 2: Disclaimer
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 2 Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer,
Slide 3: Key Performance Highlights of Q3 and 9M FY2023
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 3 Key Performance Highlights of Q3 and 9M FY2023 Financial data used on all slides ahead do not include non-common control transactions and hence YoY financial are not strictly comparable. All data used in charts are based on report
Slide 4: Key Performance Highlights of Q3 and 9M FY2023
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 4 Key Performance Highlights of Q3 and 9M FY2023 Key Highlights Revenue and EBITDA performance in Q3 FY23 (In INR Crore) Revenue EBITDA Margin Revenue grew by 11% YoY for Q3FY23 and 9MFY23 YoY Growth 25% 10% Business Segment Q3 FY
Slide 5: CDMO Business (Piramal Pharma Solutions)
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 5 CDMO Business (Piramal Pharma Solutions)
Slide 6: Contract Development and Manufacturing Organization Business
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 6 Contract Development and Manufacturing Organization Business Key Business Highlights Revenue growth in Q3 FY23 (In INR Crore) CAPEX / Expansions gone live • Ahmedabad PDS site (new In-Vitro Lab) • Significant capacity enhancemen
Slide 7: Our Strengths in the CDMO Business
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 7 Our Strengths in the CDMO Business Service Offerings Across the Lifecycle of the Molecule High Proportion of Commercial Revenues and a Deep Pipeline of Development Projects across Multiple Phases Diversified Blue Chip Customer Bas
Slide 8: Growth Drivers for CDMO Business
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 8 Growth Drivers for CDMO Business Near-term Visible Revenue Growth Levers Upsides Beyond the Plan Pursue inorganic growth Customer Focus on expanding Capability technical/product capabilities Support progression of existing and
Slide 9: Complex Hospital Generics (Piramal Critical Care)
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 9 Complex Hospital Generics (Piramal Critical Care)
Slide 10: Complex Hospital Generics Business
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 10 Complex Hospital Generics Business Key Business Highlights Revenue growth in Q3 FY23 Inhalation Anesthesia (In INR Crore) Continued momentum in Inhalation Anesthesia (IA) sales in the US with volume growth driving market share
Slide 11: Differentiated Portfolio for Gaining Market Share and Driving Growth
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 11 Differentiated Portfolio for Gaining Market Share and Driving Growth Vertically Integrated Manufacturing Capabilities with Global Differentiated portfolio spanning inhalation anesthesia and injectable Regulatory Accreditations In
Slide 12: Growth Drivers for CHG Business
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 12 Growth Drivers for CHG Business Near-term Visible Revenue Growth Levers Upsides Beyond the Plan Business acquisitions Vertical integration Differentiated portfolio Carrying out synergistic product and business Strong pipeline
Slide 13: India Consumer Healthcare (Consumer Products Division)
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 13 India Consumer Healthcare (Consumer Products Division)
Slide 14: India Consumer Healthcare Business
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 14 India Consumer Healthcare Business Key Business Highlights Revenue growth in Q3 FY23 New product launches (In INR Crore) 21 new products and 25 new SKUs launched during 9M FY23. NPDs launched in last 2 years now contribute to 1
Slide 15: Focus on Power Brands with Continuous Investments in Brand Promotion and Marketing
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 15 Focus on Power Brands with Continuous Investments in Brand Promotion and Marketing Investments in brand promotion and marketing Kareena Kapoor Priyanka Mohan Sourav Ganguly Amyra Dastur Ajay Devgan i-pill Daily Little’s Lacto - S
Slide 16: Allergan JV (India Ophthalmology Formulations)
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 16 Allergan JV (India Ophthalmology Formulations)
Slide 17: Strategic Ophthalmology JV in the Domestic Market
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 17 Strategic Ophthalmology JV in the Domestic Market Allergan India Private Limited *now AbbVie Ownership Ownership 49% 51% Key highlights of the JV The JV sells a total of 41 brands in India – key brands include It is the leade
Slide 18: Key Strategic Priorities
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 18 Key Strategic Priorities
Slide 19: Key Strategic Priorities
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 19 Key Strategic Priorities 1 Drive demand in CDMO business by increasing the proposal velocity and win rate 2 Delivering consistent revenue growth and improving profitability Track record of 3 Pursuing organic and inorganic growth
Slide 20: Financials
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 20 Financials
Slide 21: Explanation on Financial Statement
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 21 Explanation on Financial Statement Note explaining why Q3FY23 and 9MFY23 financials are strictly not comparable to Q3FY22 and 9MFY23 The Hon’ble NCLT, on 12th Aug’22, approved the composite scheme of demerger of the Pharma busine
Slide 22: Consolidated Financials Highlights – Profit & Loss Statement
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 22 Consolidated Financials Highlights – Profit & Loss Statement To arrive at like-to-like financials the below adjustments have been made in the following quarters and nine months: Q1FY23 & 9MFY23 – Excluded one-time, non-recurring
Slide 23: Dial-in details for Q3 and 9M FY2023 Earnings Conference Call
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 23 Dial-in details for Q3 and 9M FY2023 Earnings Conference Call Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) India – 5:00 PM IST 1 800 120 1221 (Toll free number) USA – 6:30 AM Toll fr
Slide 24: About Piramal Pharma Ltd.
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 24 About Piramal Pharma Ltd.
Slide 25: Piramal Pharma - Phases of our Evolution
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 25 Piramal Pharma - Phases of our Evolution 1988 2010 2020 2022 Piramal Healthcare Piramal Enterprises Piramal Pharma Ltd. Domestic Formulations Piramal Pharma Financial Services CDMO Pharma Solutions Nicholas CDMO Wholesale Lending
Slide 26: Three-Pronged Business Model with Global Operations
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 26 Three-Pronged Business Model with Global Operations Contract Development and Manufacturing Organisation Complex Hospital Generics India Consumer Healthcare (CDMO) (CHG) (ICH) 15 CDMO sites across North America, Europe and India I
Slide 27: Global Footprint with a Diversified Revenue Base
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 27 Global Footprint with a Diversified Revenue Base Revenue by Business Revenue by Geography Global Footprint 17 Manufacturing Sites in India, North ICH Others America and UK 11% 10% North CDMO America 59% India 41% 22% 100+ Countri
Slide 28: For Investor Queries:
Piramal Pharma Limited – Q3 and 9M FY2023 Results Presentation Page 28 For Investor Queries: Gagan Borana General Manager – Investor Relations & Sustainability Email : gagan.borana@piramal.com Phone : +91 22 3802 3090